Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems

被引：4

作者：

Dovc, Klemen ^{[1
,2
]}

Battelino, Tadej ^{[1
,2
]}

Beck, Roy W. ^{[3
]}

Sibayan, Judy ^{[3
]}

Bailey, Ryan J. ^{[3
]}

Calhoun, Peter ^{[3
]}

Turcotte, Christine ^{[4
]}

Weinzimer, Stuart ^{[5
]}

Schweiger, Darja Smigoc ^{[1
,2
]}

Nimri, Revital ^{[6
]}

Bergenstal, Richard M. ^{[7
]}

机构：

[1] Univ Ljubljana, Univ Med Ctr Ljubljana, Univ Childrens Hosp, Ljubljana, Slovenia

[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia

[3] Jaeb Ctr Hlth Res Fdn Inc, Tampa, FL USA

[4] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA USA

[5] Yale Univ, Dept Pediat, New Haven, CT USA

[6] Schneider Childrens Med Ctr, Petah Tiqwa, Israel

[7] HealthPartners Inst, Int Diabet Ctr, Minneapolis, MN USA

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2022年 / 24卷 / 11期

基金：

美国国家卫生研究院;

关键词：

Closed-loop systems; Continuous glucose monitoring; Insulin pump; Time in range; INSULIN DELIVERY; EXERCISE; GLUCOSE; ADULTS; ADOLESCENTS;

D O I：

10.1089/dia.2022.0153

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Medtronic advanced hybrid closed-loop (AHCL) and MiniMed (TM) 670G hybrid closed-loop (HCL) systems provide the option to temporarily increase the glucose target to 150 mg/dL (8.3 mmol/L). This analysis investigated the efficacy of the AHCL compared with that of the HCL after the use of this setting. Data from 60 participants in the Fuzzy Logic Automated Insulin Regulation (FLAIR) study were used to compare the AHCL and HCL systems after the use of the temporary target (TT), and during analogous periods where this setting was not used. Differences in time in range 70-180 mg/dL between the systems were similar after the use of the TT setting and during analogous non-TT periods (interaction P = 0.87). Similar trends were observed for mean glucose, percentage time >180 mg/dL, and percentage time >250 mg/dL. Differences between AHCL and HCL systems were similar after the use of the TT setting compared with those of non-TT periods.ClinicalTrials.gov NCT03040414

引用

页码：848 / 852

页数：5

共 50 条

[41] Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review
Farrington, C.
DIABETIC MEDICINE, 2018, 35 (04) : 436 - 449
[42] The importance of prandial insulin bolus timing with hybrid closed-loop systems
Boughton, C. K.
Hartnell, S.
Allen, J. M.
Hovorka, R.
DIABETIC MEDICINE, 2019, 36 (12) : 1716 - 1717
[43] Standardized Hybrid Closed-Loop System Reporting
Shah, Viral N.
Garg, Satish K.
DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (05) : 323 - 331
[44] Training and Support for Hybrid Closed-Loop Therapy
Boughton, Charlotte K.
Hartnell, Sara
Allen, Janet M.
Fuchs, Julia
Hovorka, Roman
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2022, 16 (01): : 218 - 223
[45] Simplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop System
Minsky, Noga
Shalit, Roy
Benedetti, Andrea
Laron-Hirsh, Maya
Cohen, Ohad
Kurtz, Natalie
Roy, Anirban
Grosman, Benyamin
Tirosh, Amir
DIABETES TECHNOLOGY & THERAPEUTICS, 2025, 27 (01) : 27 - 33
[46] LONG-TERM GLYCAEMIC OUTCOMES OF AN ADVANCED HYBRID CLOSED-LOOP SYSTEM
Beato-Vibora, P. I.
Lopez, A. Ambrojo
Fernandez-Bueso, M. M.
Gil-Poch, E.
Arroyo-Diez, F. J.
DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A106 - A107
[47] Can psychological situation determine advanced hybrid closed-loop system outcomes?
Beato Vibora, P.
Gil-Poch, E.
Arroyo-Diez, F. J.
DIABETOLOGIA, 2024, 67 : S419 - S420
[48] LESSON LEARNT WITH MINIMED 780G ADVANCED HYBRID CLOSED-LOOP
Piccini, B.
Barni, F.
Benucci, F.
Casalini, E.
Farina, S.
Laudani, E.
Lenzi, L.
Papacciuoli, V.
Toni, S.
DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A84 - A84
[49] Impact of Hybrid Closed-Loop System on Glycemic Control and Quality of Life among Japanese Individuals with Type 1 Diabetes
Mochizuki, Shota
Miura, Junnosuke
Babazono, Tetsuya
DIABETES, 2024, 73
[50] Advanced Technology (Continuous Glucose Monitoring and Advanced Hybrid Closed-Loop Systems) in Diabetes from the Perspective of Gender Differences
Nuzzo, Maria Grazia
Schettino, Marciano
DIABETOLOGY, 2023, 4 (04): : 519 - 526

← 1 2 3 4 5 →